Abstract
Induced pluripotent stem cell-derived mesenchymal stem cell-like cells (iMSCs) are considered to be a promising source of progenitor cells for approaches in the field of bone regeneration. In a previous study, we described the generation of footprint-free induced pluripotent stem cells (iPSCs) from human jaw periosteal cells (JPCs) by transfection of a self-replicating RNA (srRNA) and subsequent differentiation into functional osteogenic progenitor cells. In order to facilitate the prospective transfer into clinical practice, xeno-free reprogramming and differentiation methods were established. In this study, we compared the properties and stem cell potential of the iMSCs produced from JPC-derived iPSCs with the parental primary JPCs they were generated from. Our results demonstrated, on the one hand, a comparable differentiation potential of iMSCs and JPCs. Additionally, iMSCs showed significantly longer telomere lengths compared to JPCs indicating rejuvenation of the cells during reprogramming. On the other hand, proliferation, mitochondrial activity, and senescence-associated beta-galactosidase (SA-β-gal) activity indicated early senescence of iMSCs. These data demonstrate the requirement of further optimization strategies to improve mesenchymal development of JPC-derived iPSCs in order to take advantage of the best features of reprogrammed and rejuvenated cells.
Highlights
A growing population and aging societies lead to a rising demand for regenerative therapies in the field of orthopedic and maxillofacial surgery
Tri-Lineage Differentiation of iMSCs and jaw periosteal cells (JPCs) induced pluripotent stem cells (iPSCs) were generated from JPCs of three different donors and differentiated into iMSCs
To demonstrate their differentiation potential, iMSCs were differentiated into the adipogenic, chondrogenic, and osteogenic lineage
Summary
A growing population and aging societies lead to a rising demand for regenerative therapies in the field of orthopedic and maxillofacial surgery. In addition to classical treatments, cell therapies and tissue engineering approaches are pushing their way into clinical applications. For these purposes, mesenchymal stem/stromal cells (MSCs) isolated from different tissues are being tested in clinical trials [1]. Mesenchymal stem/stromal cells (MSCs) isolated from different tissues are being tested in clinical trials [1] Based on their stem cell potential, homing activity, and immunomodulatory properties, MSCs can be applied for the treatment of a variety of diseases [2,3,4]. It is unfavorable that the quantity of MSCs in donor tissues decreases with age [6] as older patients make up the majority of the patients in need of such treatments
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
